{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:31:39Z","timestamp":1793457099722,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck KGaA, Darmstadt, Germany","id":[{"id":"https:\/\/ror.org\/04b2dty93","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.msard.2019.01.038","type":"journal-article","created":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T06:09:05Z","timestamp":1548569345000},"page":"168-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":144,"special_numbering":"C","title":["Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis"],"prefix":"10.1016","volume":"29","author":[{"given":"Giancarlo","family":"Comi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rieckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Soelberg","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Galazka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Nolting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hicking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Dangond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2019.01.038_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/2231-0770.114121","article-title":"Idiopathic CD4 Lymphocytopenia: spectrum of opportunistic infections, malignancies, and autoimmune diseases","volume":"3","author":"Ahmad","year":"2013","journal-title":"Avicenna J. Med."},{"issue":"4","key":"10.1016\/j.msard.2019.01.038_bib0017","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1212\/NXI.0000000000000360","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.msard.2019.01.038_bib0020","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the Pivotal Phase 3 Trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol."},{"issue":"8825","key":"10.1016\/j.msard.2019.01.038_bib0003","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","article-title":"Cladribine (2-chlorodeoxyadenosine)","volume":"340","author":"Beutler","year":"1992","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.msard.2019.01.038_bib0004","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/14656566.2013.754012","article-title":"Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis","volume":"14","author":"Comi","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.msard.2019.01.038_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617753365","article-title":"Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study","volume":"11","author":"Comi","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2019.01.038_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2018.10.091","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","author":"Cook","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2019.01.038_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines6010006","article-title":"Non melanoma skin cancer pathogenesis overview","volume":"6","author":"Didona","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.msard.2019.01.038_bib0022","unstructured":"European Medicines Agency. European Public Assessment Report: Mavenclad. 2017 [cited; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR - Public_assessment_report\/human\/004230\/WC500234563.pdf."},{"issue":"1","key":"10.1016\/j.msard.2019.01.038_bib0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ajh.23862","article-title":"Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news?","volume":"90","author":"Freyer","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.msard.2019.01.038_bib0006","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"S3","key":"10.1016\/j.msard.2019.01.038_bib0030","article-title":"Durable efficacy of cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies","volume":"22","author":"Giovannoni","year":"2016","journal-title":"Mult. Scler. J."},{"issue":"12","key":"10.1016\/j.msard.2019.01.038_bib0007","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2017","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2019.01.038_bib0001","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to treat relapsing forms of multiple sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.msard.2019.01.038_bib0014","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2019.01.038_bib0029","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12883-017-0848-8","article-title":"Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies","volume":"17","author":"Holmoy","year":"2017","journal-title":"BMC Neurol."},{"issue":"5","key":"10.1016\/j.msard.2019.01.038_bib0024","first-page":"1235","article-title":"Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia","volume":"54","author":"Kearns","year":"1994","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.msard.2019.01.038_bib0019","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.intimp.2013.11.027","article-title":"Cladribine exerts an immunomodulatory effect on human and murine dendritic cells","volume":"18","author":"Kraus","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.msard.2019.01.038_bib0012","article-title":"The incidence of non-melanoma skin cancer and post-transplant lympho-proliferative disorders in the Scottish cardiac transplant population and the provision of specialist dermatological follow-up","author":"McPherson","year":"2017","journal-title":"Scott. Med. J."},{"issue":"3","key":"10.1016\/j.msard.2019.01.038_bib0018","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2019.01.038_bib0009","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.canep.2011.12.002","article-title":"Comparative incidence of cancer in HIV-AIDS patients and transplant recipients","volume":"36","author":"Oliveira Cobucci","year":"2012","journal-title":"Cancer Epidemiol."},{"issue":"4","key":"10.1016\/j.msard.2019.01.038_bib0013","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/ijd.13409","article-title":"Basic aspects of the pathogenesis and prevention of non-melanoma skin cancer in solid organ transplant recipients: a review","volume":"56","author":"Perez","year":"2017","journal-title":"Int. J. Dermatol."},{"issue":"3","key":"10.1016\/j.msard.2019.01.038_bib0023","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.1996.14.3.978","article-title":"Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy","volume":"14","author":"Saven","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"S3","key":"10.1016\/j.msard.2019.01.038_bib0027","first-page":"598","article-title":"1141: innate immune cell counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5\u202fmg\/kg in CLARITY and CLARITY Extension","volume":"23","author":"Soelberg Sorensen","year":"2017","journal-title":"Mult. Scler. J."},{"issue":"S3","key":"10.1016\/j.msard.2019.01.038_bib0028","first-page":"335","article-title":"P690: cladribine tablets produce selective and discontinuous reduction of B and T lymphocytes and natural killer cells in patients with early and relapsing multiple sclerosis (ORACLE-MS, CLARITY and CLARITY Extension)","volume":"23","author":"Stuve","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2019.01.038_bib0021","article-title":"Effects of postponing treatment in the second year of cladribine administration: clinical trial simulation analysis of absolute lymphocyte counts and relapse rate in patients with relapsing-remitting multiple sclerosis","author":"Terranova","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.msard.2019.01.038_bib0016","unstructured":"Territo M. Lymphocytopenia. MSD Manual, Professional Version 2016 [cited; Available from: http:\/\/www.msdmanuals.com\/en-gb\/professional\/hematology-and-oncology\/leukopenias\/lymphocytopenia."},{"issue":"1","key":"10.1016\/j.msard.2019.01.038_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/COH.0b013e32835b8123","article-title":"Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges","volume":"8","author":"Vitoria","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"10","key":"10.1016\/j.msard.2019.01.038_bib0002","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2017.119","article-title":"Cladribine - an old newcomer for pulsed immune reconstitution in MS","volume":"13","author":"Wiendl","year":"2017","journal-title":"Nature Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819300392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819300392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:45:14Z","timestamp":1761900314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819300392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":29,"alternative-id":["S2211034819300392"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.01.038","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}